Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Prostate Cancer

Free Subscription 10.11.2025 1 AJR Am J Roentgenol 3 BJU Int 3 BMC Cancer 1 BMC Urol 1 Cancer 2 Cancer Res 3 Eur Radiol 1 Eur Urol 1 Int J Cancer 4 Int J Urol 1 J Magn Reson Imaging 1 J Natl Cancer Inst 5 J Nucl Med 1 J Urol 1 Oncogene 5 PLoS One 3 Prostate 1 Ther Adv Urol 1 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. KRISHNA S, Bhayana R
   Biparametric MRI: Toward a Faster, Cheaper, Contrast-Media-Free Standard for Prostate Cancer Diagnosis.
   AJR Am J Roentgenol. 2025 Nov 5. doi: 10.2214/AJR.25.34135.
   PubMed        
   
   

   
   BJU Int

2. DAS A, Bigarella M, Brackman K, Allen GO, et al
   Prostate zonal impact of 5alpha-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
   BJU Int. 2025 Nov 5. doi: 10.1111/bju.70067.
   PubMed         Abstract available
   
   
3. BUSHATI Y, Guo AA, Muston BT, Bushati A, et al
   Focal laser ablation in prostate cancer: a systematic review and meta-analysis.
   BJU Int. 2025 Nov 4. doi: 10.1111/bju.70064.
   PubMed         Abstract available
   
   
4. SOON YY, Marschner IC, Schou IM, Sweeney CJ, et al
   Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
   BJU Int. 2025 Nov 5. doi: 10.1111/bju.70065.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. HUA J, Qian Y, Lu Y, Zhang Q, et al
   Cross-tissue transcriptome-wide association studies identify genetic susceptibility genes for prostate cancer.
   BMC Cancer. 2025;25:1708.
   PubMed         Abstract available
   
   
6. ROSE-DITE-MODESTINE J, Vallard A, Loger JS, Merle S, et al
   Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort.
   BMC Cancer. 2025;25:1703.
   PubMed         Abstract available
   
   
7. WANG Y, Wang J, Ren G
   UHRF1 and NF-kappaB signaling in prostate cancer progression insights from bioinformatics and experimental validation.
   BMC Cancer. 2025;25:1697.
   PubMed         Abstract available
   
   

   
   BMC Urol

8. YAHSI S, Oksuz P, Ceviz K, Ceylan C, et al
   NPRL2 gene expression as a predictor of biochemical recurrence after robot-assisted radical prostatectomy.
   BMC Urol. 2025;25:275.
   PubMed         Abstract available
   
   

   
   Cancer

9. LIU MA, Raghunathan R, Runcie K, Wooster M, et al
   Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors.
   Cancer. 2025;131:e70163.
   PubMed         Abstract available
   
   

   
   Cancer Res

10. ANZULES JM, Sayegh M, Li YR
    Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer.
    Cancer Res. 2025;85:4045-4046.
    PubMed         Abstract available
    
    
11. MARSILIO L, Barrios S, Maksimovic S, Maccarini A, et al
    In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response.
    Cancer Res. 2025;85:4269-4284.
    PubMed         Abstract available
    
    

    
    Eur Radiol

12. WOO S, Russo L, Withey SJ, Dehghanpour A, et al
    ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer.
    Eur Radiol. 2025 Nov 5. doi: 10.1007/s00330-025-12089.
    PubMed         Abstract available
    
    
13. VAN DEN KROONENBERG DL, Delberghe F, Jager A, Postema AW, et al
    Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localizing clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2025 Nov 6. doi: 10.1007/s00330-025-12114.
    PubMed         Abstract available
    
    
14. BARENTSZ JO, Ahmed HU, Miszczyk M, Catalano C, et al
    ESR Bridges: early-stage prostate cancer: new developments in imaging and treatment-a multidisciplinary view.
    Eur Radiol. 2025 Nov 7. doi: 10.1007/s00330-025-12125.
    PubMed        
    
    

    
    Eur Urol

15. RIAZ IB, Ahmed Naqvi SA, Faisal KS, He H, et al
    Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
    Eur Urol. 2025 Nov 4:S0302-2838(25)00509-3. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    

    
    Int J Cancer

16. SABBAGHIAN A, Lin H, Lim YP
    WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers.
    Int J Cancer. 2026;158:218-231.
    PubMed         Abstract available
    
    

    
    Int J Urol

17. NAKAMURA M, Muraki Y, Yamada Y, Matsumoto S, et al
    Impact of Enhanced Recovery After Surgery Protocol on Perioperative Quality of Life in Robot-Assisted Radical Prostatectomy: A Single-Center Prospective Cohort Study.
    Int J Urol. 2025;32:1561-1568.
    PubMed         Abstract available
    
    
18. KOHADA Y, Kitano H, Tasaka S, Ono Y, et al
    Association Between Preoperative Penile Circumference and Urinary Function After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1576-1586.
    PubMed         Abstract available
    
    
19. NISHINO T, Shimbo M, Sano M, Oguchi T, et al
    Incidence, Risk Factors, and Clinical Characteristics of Late Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:1688-1695.
    PubMed         Abstract available
    
    
20. KANEKO G
    Editorial Comment to "Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study".
    Int J Urol. 2025 Nov 4. doi: 10.1111/iju.70278.
    PubMed        
    
    

    
    J Magn Reson Imaging

21. PERSILY J, Chandarana H, Tong A, Ranganath R, et al
    Development and Deployment of a Machine Learning Model to Triage the Use of Prostate MRI (ProMT-ML) in Patients With Suspected Prostate Cancer.
    J Magn Reson Imaging. 2025 Nov 4. doi: 10.1002/jmri.70162.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

22. DE FERIA CARDET RE, Goodall S, Laba TL, Haas M, et al
    What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment.
    J Natl Cancer Inst. 2025 Nov 3:djaf315. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

23. KUNSCH J, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [(177)Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT.
    J Nucl Med. 2025 Sep 11:jnumed.125.270358. doi: 10.2967/jnumed.125.270358.
    PubMed         Abstract available
    
    
24. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with (177)Lu-PSMA: A Retrospective, Single-Center Study.
    J Nucl Med. 2025 Sep 25:jnumed.125.269971. doi: 10.2967/jnumed.125.269971.
    PubMed         Abstract available
    
    
25. KRAUSEWITZ P, Essler M, Gaertner FC, Attenberger U, et al
    Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP Trial.
    J Nucl Med. 2025 Nov 6:jnumed.125.271344. doi: 10.2967/jnumed.125.271344.
    PubMed         Abstract available
    
    
26. MIRSHAHVALAD SA, Iravani A, Fendler WP, Maurer T, et al
    Rechallenge and Extended [(177)Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270889. doi: 10.2967/jnumed.125.270889.
    PubMed         Abstract available
    
    
27. ORTNER G, Hoderlein X, Barbato F, Beyersdorff D, et al
    The Pelvic Rosetta Classification Project: An Interdisciplinary Proposal for a Lymph Node Map of the Pelvis in Prostate Cancer.
    J Nucl Med. 2025 Nov 6:jnumed.125.270667. doi: 10.2967/jnumed.125.270667.
    PubMed         Abstract available
    
    

    
    J Urol

28. FENG Y, Zhou S, Huang S, Yu Z, et al
    Letter: The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomo
    J Urol. 2025 Nov 5:101097JU0000000000004787. doi: 10.1097/JU.0000000000004787.
    PubMed        
    
    

    
    Oncogene

29. CHEN J, Wang ME, Bawcom AR, Lu Y, et al
    Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation.
    Oncogene. 2025;44:4405-4412.
    PubMed         Abstract available
    
    

    
    PLoS One

30. MEDINA S, Romero E, Cruz-Roa A, Gonzalez FA, et al
    Interpretable weakly-supervised learning through kernel density matrices: A digital pathology use case.
    PLoS One. 2025;20:e0335826.
    PubMed         Abstract available
    
    
31. 
    Retraction: Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
    PLoS One. 2025;20:e0336085.
    PubMed        
    
    
32. QIN X, Han M, Hu P, Que H, et al
    Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors.
    PLoS One. 2025;20:e0334632.
    PubMed         Abstract available
    
    
33. YAGHOBINEJAD M, Naji M, Alizadeh AM, Aryanezhad S, et al
    Identification and validation of stage-specific microRNAs and target genes for prostate cancer: Utilizing bioinformatics tools for diagnostic marker discovery.
    PLoS One. 2025;20:e0315366.
    PubMed         Abstract available
    
    
34. KONG P, Yang L, Wang H, Liu Z, et al
    The relationship between the neutrophil percentage to albumin ratio and the occurrence of prostate cancer.
    PLoS One. 2025;20:e0334426.
    PubMed         Abstract available
    
    

    
    Prostate

35. SHI R, Du Q, Yao C, Huang D, et al
    The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients.
    Prostate. 2025 Nov 4. doi: 10.1002/pros.70089.
    PubMed         Abstract available
    
    
36. GOMEZ-LUQUE MA, Rodriguez-Marcos P, Campanario-Perez R, Medina-Gonzalez A, et al
    Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer.
    Prostate. 2025 Nov 4. doi: 10.1002/pros.70088.
    PubMed         Abstract available
    
    
37. NARITA S, Yanagisawa T, Hatakeyama S, Fukuokaya W, et al
    The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2025 Nov 6. doi: 10.1002/pros.70092.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

38. FARZAT M, Wagenlehner FM
    Incidental prostate cancer: is prostate-specific antigen density a valid predictor? A case-control study.
    Ther Adv Urol. 2025;17:17562872251386996.
    PubMed         Abstract available
    
    

    
    Urol Int

39. GORGEL SN, Akin Y, Yorulmaz EM, Donmez K, et al
    Predictive Value of Node-RADS for Lymph Node Involvement in Prostate Cancer: A Matched Cohort Study.
    Urol Int. 2025 Nov 3:1-19. doi: 10.1159/000549303.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.